1 |
Lee JH, Lee YC, Jeon SW, et al. Guidelines of Prevention and Treatment for NSAID-related Peptic Ulcers. Korean J Gastroenterol 2009; 54: 309-317.
DOI
ScienceOn
|
2 |
Breninan MR, Chiun-Fang Chiou, Joshua J. Minimizing Complications From Nonsteroidal Antiinflammatory Drugs: Cost-Effectiveness of Competing Strategies in Varying Risk Groups. Arthritis & Rheumatism 2005; 53(2): 185-97.
DOI
ScienceOn
|
3 |
Laura E. Peter A. Gastroprotective strategies among NSAID users. Can Fam Physician 2006; 52: 1100-5.
|
4 |
Guidelines for Use of NSAIDs and COX-2 selective agents; the ASHP web page at http://www.ashp.org.
|
5 |
James KK, Graham Sleat, Sunil Sharma, et al. Gastroprotection in trauma patiets receiving non-steroidal anti-inflammatory drugs. The surgeon 2010; 8: 206-10.
DOI
ScienceOn
|
6 |
Kristina J, Johan F. Concomitant Use of Gastroprotective Drugs among Elderly NSAID/COX-2 Selective Ihnibitor Users. Clin Drug Invest 2008; 11: 687-95.
|
7 |
Cho J, Lee E, Shin WG. Evaluation of NSAID Usage and Appropriateness for Prevention of NSIAD-related Ulcer Complications. Kor J Clin Pharm 2012; 22(3): 212-9.
|
8 |
Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazle compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 338: 727-34.
DOI
ScienceOn
|
9 |
Rose P, Huang B. Evidence that lansoprazole is effective in preventing NSAID induced ulcers. Gastroenterology 1999; 116:A295.
|
10 |
Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal antiinflammatory drugs. A randomized, double-blind, placebocontrolled trial. Ann Intern Med 1995; 123: 241-9.
DOI
ScienceOn
|
11 |
Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritic patients taking NSAIDs. Ann Inter Med 1993; 119: 257-62.
DOI
ScienceOn
|
12 |
Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-infammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995; 123: 344-50.
DOI
ScienceOn
|
13 |
Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996; 334: 1435-9.
DOI
ScienceOn
|
14 |
Elsa Lopez-Pintor, Blanca Lumbreras. Use of gastrointestinal prophylaxis in NSAID patients: a cross sectional study in community pharmacies. Int J Clin Pharm 2011; 33: 155-164.
DOI
|
15 |
Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: c7086.
DOI
ScienceOn
|
16 |
Francesca CL, Muredach P, Shiv CK, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-17.
DOI
ScienceOn
|
17 |
Patrignani P, Tacconelli S, Bruno A, et al. Managing the adverse effects of nonsteroidal anti-inflammatory drugs. Expert Rev Clin Pharmacol 2011; 4: 605-21.
DOI
ScienceOn
|
18 |
Renda G, Tacconelli S, Capone ML, et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmaco Ther 2006; 80: 264-74.
DOI
ScienceOn
|
19 |
Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005; 45: 1295-1301.
DOI
ScienceOn
|
20 |
LEE GY, Jeon ES. How to Use NSAID in Patients with Cardiovascular Disease. J Orthop Pain Society 2012; 2: 40-3.
|
21 |
Graham DY, Chan FK. NSAIDs, risk, and gastropretective strategies: current status and futures. Gastroenterology 2008; 134: 1240-6.
DOI
ScienceOn
|
22 |
Barat I, Aadrease F, Damsgaard EM. The consumption of drugs by 75-year old individual living in their own homes. Eur J Cln Pharmcol 2000; 56: 501-9.
DOI
ScienceOn
|
23 |
Larkai EN, Smith JL, Lidsky MD, et al. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic NSAIDs use. Am J Gastroenterol 1987; 82: 1153-8.
|
24 |
Laine L. Approaches to Nonsteroidal Anti-inflammatory Drug Use in the High-Risk Patient. Gastroenterology 2001; 120: 594-606.
DOI
ScienceOn
|
25 |
Kim DS. The dupication of NSAIDs and management plan. HIRA Policy Trend 2013; 7(4): 7-8.
|
26 |
Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin North Am 1996; 6: 489-504.
|
27 |
Silverstein FE, Faich G, Jay L. et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety study. JAMA 2000; 284: 1247-55.
DOI
ScienceOn
|
28 |
Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoixb and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med 2000; 343: 1520-8.
DOI
ScienceOn
|
29 |
Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 2000: 119: 521-35.
DOI
ScienceOn
|
30 |
McGettign P, Henry D. Cardiovascular risk and inhibition of cycooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cycloocygenase 2. JAMA 2006; 296: 1633-44.
DOI
ScienceOn
|
31 |
Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071-3.
DOI
ScienceOn
|
32 |
Kearney PM, Baigent C, Godwin J, et al. Do selective COX-2 inhibitors and nonselective NSAIDs increase the risk of atherothrombosis, Meta-anaylsis of randomised trials. BMJ 2006; 332: 1302-8.
DOI
ScienceOn
|
33 |
Abraham NS, El-Serag HB, Hartman C, et al. Cyclooxygenase-2 selectivity of NSAIDs and the risk of myocardial infarction and cerebrovascular accident. Aliment Pharmacol Ther 2007; 25: 913-24.
DOI
ScienceOn
|
34 |
Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: An update for clinicians: A scientific statement from the American Heart Association. Circulation 2007; 115(12): 1634-42.
DOI
ScienceOn
|
35 |
NSAIDs Prescribig Issues; NICE (National Institute for Health and Clinical Excellence) web page at http://cks.nice. org.uk/nsaids-prescribing-issues (Last revised in January 2013).
|
36 |
Francis KL, Neena S. James M, et al. Management of Patients on NSAID: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of NSAIDs and Antiplatelets agents: Am J Gastroenterol 2008; 103: 2908-18.
DOI
ScienceOn
|
37 |
Frank L, Francis KL, Eamonn MM. Guidelines for Prevention of NSAID-Related Ulcer Complications: Am J Gastroenterol 2009; 104: 728-38.
DOI
ScienceOn
|
38 |
James M, Clemence E. Strategies to optimize Treatment with NSAIDs in Patients at Risk for Gastrointestinal and Cardiovascular Adverse Event: Clin Ther 2010; 32: 667-77.
DOI
ScienceOn
|